Dexcom Stelo launched in 2024 as the first FDA-authorized over-the-counter CGM — no prescription required. It targets people with Type 2 diabetes not on insulin, and the broader metabolic health market. Here is our hands-on assessment.
What Is Dexcom Stelo?
Stelo is a CGM system specifically designed for people who do not use insulin. It uses the same interstitial glucose measurement technology as the G7 but with a different form factor and no urgent low alerts — because hypoglycemia is not a concern for its target user.
Accuracy
Stelo carries a MARD of 8.7%, which is comparable to the G7 and clinically acceptable. Real-world testing shows it tracks well during stable glucose periods. Like all CGMs, it lags during rapid changes.
Key Specs
- Wear time: 15 days (longest in the Dexcom family)
- No fingerstick calibration required
- No separate receiver — phone only (iOS and Android)
- No urgent low alert (by design — not for insulin users)
- Cost: ~$99/month for two sensors (OTC, no insurance needed)
Who Is It For?
Stelo is ideal for:
- Type 2 diabetes managed with diet, oral medications, or GLP-1 agonists (not insulin)
- Pre-diabetics wanting to track glucose trends
- Health-conscious individuals tracking metabolic health (a growing use case in 2025-2026)
It is not suitable for Type 1 diabetes, Type 2 on insulin, or anyone with severe hypoglycemia risk.
Abbott Lingo vs Dexcom Stelo
Abbott launched its own OTC CGM (Lingo) in the same period. Both have 15-day sensors. Lingo’s app focuses more on lifestyle coaching; Stelo’s app is simpler and data-focused. Stelo edges ahead for raw data access.
Verdict
Stelo is a legitimate product that removes the biggest barrier to CGM adoption: the prescription requirement. At $99/month OTC, it is accessible to millions who could benefit from glucose visibility. If you are on insulin, use the G7 instead.